期刊
ANNALS OF NEUROLOGY
卷 55, 期 3, 页码 422-426出版社
WILEY
DOI: 10.1002/ana.20052
关键词
-
资金
- NIGMS NIH HHS [R01 GM 48152] Funding Source: Medline
- NINDS NIH HHS [R01 NS 43264] Funding Source: Medline
We report the translational readthrough levels induced by the aminoglycosides gentamicin, amikacin, tobramycin, and paromomycin for eight premature stop codon mutations identified in Duchenne's and Becker's muscular dystrophy patients. In a transient transfection reporter assay, aminoglycoside treatment results show that one stop codon mutation is suppressed significantly better (up to 10% stop codon readthrough) than the others; five show lower but statistically significant suppression (<2% stop codon readthrough); and two appear refractory to aminoglycoside treatment. Readthrough levels do not substantially vary between different sources of gentamicin, and, for this set of mutations, the efficiency of termination at the premature stop codon mutation does not appear to correlate with disease severity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据